Loratadine Dosing
For adults and children ≥6 years, use loratadine 10 mg once daily; for children 2 to under 6 years, use 5 mg once daily; and for patients with liver or kidney disease, consult specific guidance before dosing. 1
Standard Dosing by Age
Based on FDA labeling, the recommended doses are:
- Adults and children ≥6 years: 10 mg (2 teaspoonfuls of 5 mg/5 mL solution) once daily 1
- Children 2 to under 6 years: 5 mg (1 teaspoonful) once daily 1
- Children under 2 years: Requires physician consultation 1
Do not exceed the recommended daily dose within 24 hours 1
Dose Adjustments for Special Populations
Renal Impairment
The disposition of loratadine is not significantly altered in patients with severe renal insufficiency (creatinine clearance <30 mL/min), and hemodialysis removes less than 1% of the drug 2. However, the metabolite descarboethoxyloratadine (desloratadine) shows significantly increased AUC in patients with chronic renal failure 2. The FDA label recommends consulting a physician for patients with kidney disease before dosing 1, suggesting caution despite minimal pharmacokinetic changes to the parent compound.
Hepatic Impairment
Patients with liver disease should consult a physician before using loratadine 1. While specific dose adjustments are not detailed in the provided FDA labeling, hepatic metabolism is a primary elimination pathway, warranting medical supervision.
Elderly Patients
The guideline evidence suggests age-stratified dosing for oral antihistamines in general, with recommendations for ages 66-76 years at 5-10 mg/day and ≥77 years at 5 mg/day 3. However, the FDA label for loratadine does not specify different dosing for elderly patients 1. Given that loratadine pharmacokinetics in renal impairment show minimal changes 2, standard adult dosing of 10 mg daily appears appropriate for elderly patients without significant hepatic impairment, though clinical judgment should guide individual cases.
Clinical Context
Loratadine is a second-generation antihistamine with minimal sedation at standard doses compared to first-generation agents 4. In children aged 2-5 years, the 5 mg dose provides exposure similar to the adult 10 mg dose and is well tolerated 5. The drug demonstrates fast onset of action and once-daily convenience 4, making it appropriate first-line therapy for allergic rhinitis and chronic urticaria 6, 4.
Common Pitfalls
- Avoid exceeding recommended doses: Higher doses may increase sedation risk 3
- Liver/kidney disease requires consultation: Despite favorable pharmacokinetics in renal failure, the FDA mandates physician guidance for organ impairment 1
- Not approved for children <2 years: Safety and efficacy not established in this age group 1